See the DrugPatentWatch profile for Lamzede
What is Lamzede?
Lamzede is the brand name for velmanase alfa, an enzyme replacement therapy used for mucopolysaccharidosis type IV A (Morquio A syndrome)—a rare inherited lysosomal storage disorder caused by deficiency of the enzyme N-acetylgalactosamine-6-sulfatase. By replacing the missing enzyme, it helps address the underlying biochemical defect. [1]
Who is it for, and what does treatment target?
Lamzede is prescribed for patients with Morquio A. The goal of enzyme replacement therapy is to reduce disease burden driven by accumulation of glycosaminoglycans in tissues, and to help improve or stabilize aspects of the condition that respond to enzyme therapy. [1]
How is Lamzede given?
Lamzede is administered by intravenous (IV) infusion. [1]
How does Lamzede compare with other approaches?
For Morquio A, other management typically focuses on supportive care and symptom management (for example, orthopedic, respiratory, and cardiac monitoring). Lamzede is the disease-directed therapy because it replaces the missing enzyme. [1]
What side effects do people ask about?
Common concerns with IV enzyme therapies include infusion-related reactions (symptoms that can occur during or shortly after the infusion). If you tell me the age of the patient and where you are in treatment (starting vs already on therapy), I can tailor a more specific side-effect checklist based on the information you have.
Where can I find official prescribing information?
The most reliable details on dosing schedules, infusion procedures, warnings, and contraindications come from the official prescribing information for Lamzede. [1]
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201949